A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Tralokinumab is effective in severe atopic dermatitis for up to 18 months, with patients who are naïve to some medications having faster benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback